A Study Testing the Effectiveness and Safety of KPL-301 in Patients with Giant Cell Arteritis

Overview

About this study

The primary purpose of this study is to evaluate the effectiveness and safety of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new onset or relapsing/refractory giant cell arteritis (GCA).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria: 

  • Subjects with new-onset or relapsing/refractory GCA. 
  • Westergren erythrocyte sedimentation rate > 30 mm/hour or c-reactive protein ≥ 1 mg/ dL. 
  • Remission of GCA at or before Day 0. 
  • Female subjects must be postmenopausal or permanently sterile following documented hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or tubal ligation or having a male partner with vasectomy as affirmed by the subject, or nonpregnant, nonlactating, and, if sexually active, having agreed to use a highly effective method of contraception. 
  • Male subjects must have documented vasectomy or if sexually active must agree to use a highly effective method of contraception with their partners of childbearing potential.

Exclusion Criteria: 

  • Transplanted organs (except corneal transplant performed more than 3 months prior to randomization). 
  • Concurrent enrollment in another interventional clinical study. 
  • Treatment with non-biologic investigational drug therapy within 4 weeks or 5 half-lives of the study agent, whichever was longer, prior to screening. 
  • Cell-depleting biological therapies within 12 months prior to Day 0, or noncell-depleting biological therapies within 8 weeks (or 5 half-lives, whichever is longer) prior to screening.
  • Treatment with alkylating agents within 12 weeks prior to screening. 
  • Intramuscular, Intra-articular or IV corticosteroids within 4 weeks prior to screening.
  • Receipt of live (attenuated) vaccine within the 4 weeks before Day 0. 
  • Treatment with hydroxychloroquine, cyclosporine A, azathioprine, cyclophosphamide, or mycophenolate mofetil (MMF) within 4 weeks of screening. 
  • Female subjects who are pregnant, intending to become pregnant, or are breastfeeding. 
  • Known history of allergy or reaction to any component of the mavrilimumab or placebo formulation or to any other biologic therapy or prednisone or any of its excipients. 
  • Positive (or 2 indeterminate) QuantiFERON test results. 
  • Clinically significant active infection or infection requiring hospitalization or IV antibiotics within 12 weeks before screening or opportunistic infection within 6 months before screening. 
  • Chronic active hepatitis B infection. 
  • Subjects at a high risk of infection, a history of an infected joint prosthesis still in situ, leg ulcers, indwelling urinary catheter, or persistent or recurrent chest infections. 
  • History of cancer within the last 10 years, except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured. 
  • Evidence of clinically-uncontrolled respiratory disease. 
  • History of chronic respiratory tract infections.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kenneth Warrington, M.D.

Open for enrollment

Contact information:

Jane Jaquith C.C.R.C.

(507) 284-4502

jaquith.jane@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20459308

Mayo Clinic Footer